CTConor Duncan Tweed

Conor Duncan Tweed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Conor Duncan Tweed has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring Heterogeneity in Meta‐Analysis Using Trial‐Level Characteristics: A Tutorial

    by Peter J. Godolphin, Conor D. Tweed, David J. Fisher

    This tutorial describes how to explore across‐trial heterogeneity in meta‐analysis using trial‐level characteristics. It describes how to carry out a subgroup analysis for a trial‐level characteristic with more than two categories and provides approaches for analysing continuous trial‐level characteristics. The tutorial introduces meta‐regression, outlines its intended applications, and explains how to interpret meta‐regression results. Common pitfalls when undertaking trial‐level subgroup analysis and meta‐regression are also discussed. A complementary micro‐learning module is provided to support additional learning of these concepts.


  • Open Access

    Introduction to Trial‐Level Subgroup Analysis: A Tutorial

    by Peter J. Godolphin, Conor D. Tweed, David J. Fisher

    This tutorial introduces the concept of trial‐level subgroup analysis in meta‐analysis. We describe the rationale for conducting subgroup analyses, distinguish trial‐level from participant‐level characteristics, outline how to properly interpret effects within subgroups, and illustrate how to perform a trial‐level subgroup analysis, including formal statistical testing for differences between subgroups. A complementary micro‐learning module is provided to support additional learning of these concepts.


  • Open Access

    Evaluation of person-centred outcome measures for use in clinical trials of tuberculosis therapeutics

    by Conor D Tweed, Annabelle South, Suzanne Staples, Bazarragchaa Tsogt, Nestani Tukvadze, Rebecca M Turner, Stephan Dressler, Adam T Gray, Blessina Kumar, Oxana Rucsineanu, et al.

    Background: There is a need for person-centred outcome measures (PCOMs) in tuberculosis (TB) clinical trials to capture the priorities of affected individuals relating to both disease and treatment, alongside the traditional efficacy and safety analysis. Methods: We conducted a literature search to identify existing health-related quality-of-life (HR-QoL) measurement tools and instances where they have been used to evaluate TB disease in interventional studies. DR-TB survivors were recruited for focus group discussions in South Africa, Mongolia and Georgia to determine the most important aspects of disease and treatment experience from their perspective. A second round of focus groups then worked to prioritise these items and group them within different domains. A panel of researchers and academic clinicians evaluated existing PCOMs identified in the literature search using a published framework. Finally, an assessment was carried out by a experienced TB Community Advisory Group members for appropriateness and acceptability, and clinical trial site investigators for feasibility of the PCOMs. Results: The initial round of 9 focus groups involving 57 participants identified priority items grouped under the fields “overall quality of life”, “disease symptoms”, and “treatment and side effects”. In the second round of four focus groups involving 26 participants, the highest ranked items under “overall quality of life” were duration of treatment, experience of swallowing pills, and how long before being able to contribute to the household. The most important symptoms were coughing, weight loss and breathlessness. The highest ranked side effects were nausea/vomiting, skin colour changes, and nerve problems. FACIT-TB was the only measurement tool assessed that was rated “good” for appropriateness, and “excellent”, “good” or “fair” in all other fields by community representatives, researchers and clinical trial site staff. Conclusions: The FACIT-TB measurement tool was identified as the most appropriate disease-specific PCOM currently available for use in clinical trials investigating novel DR-TB therapeutics.

  • Open Access

    Exploring different objectives in non-inferiority trials

    by Conor D Tweed, Matteo Quartagno, Michelle N Clements, Rebecca M Turner, Andrew J Nunn, David T Dunn, Ian R White, Andrew J Copas

    Non-inferiority trials compare the efficacy of a new treatment with an existing one where the new treatment is expected to have broadly similar efficacy to the existing treatment, but where other benefits might make the new treatment desirable. These trials might aim to demonstrate that a new treatment is either an alternative to, or a replacement for, the current treatment. In this article, how treatment comparisons can be based only on efficacy, or on both efficacy and other benefits, is explained, and guidance on how to choose the correct objective for a trial is given. This choice should influence the design of the trial (eg, choosing the non-inferiority margin and secondary outcomes), analysis, and reporting of the trial. Most non-inferiority trials aim to show only that a new treatment is an alternative to the standard of care. Being more transparent about the trial objective, however, could mean that more trials are conducted with an emphasis on the risk-benefit trade-off for a new treatment and generate more clinically meaningful trial results with a greater effect on practice.


  • Open Access

    Patients’ priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia

    by Annabelle South, Parveen Dhesi, Conor D. Tweed, Bazarragchaa Tsogt, Suzanne Staples, Nestani Tukvadze, Gantsetseg Dorj, Sindisiwe Zaca, Ekaterine Sanikidze, Nasanjargal Purev, et al.

    We conducted qualitative research exploring the treatment experience of people with DR-TB. We held nine focus group discussions with 57 adults undergoing/recently completed treatment for DR-TB in Georgia, Mongolia and South Africa. Translated transcripts were analysed using thematic analysis. We identified three higher order themes: (1) Treatment experience and the role of good relationships with healthcare providers: Treatment duration, pill burden and side-effects were challenging aspects of treatment. Side-effects/symptoms that were visible signs of illness were particularly troubling. Good relations with clinical staff helped combat fear and uncertainty regarding treatment. (2) Mental distress and opportunities for wellbeing: The shame, stigma and isolation people experienced as a result of their DR-TB diagnosis was an important cause of mental distress. No longer being infectious enabled people to resume work and socialising. Positive emotions emerged with good treatment outcomes. (3) Fear and worry along the treatment journey: Participants expressed fears about TB: infecting others; whether they would be able to endure treatment; side-effects; health consequences of treatment. Worries mostly disappeared with successful treatment. Alongside measuring side-effects, time to culture conversion and cure rates, future trials of DR-TB treatments should capture how quickly visible symptoms resolve, quality of life measures, and mental health outcomes.


  • Top Cited Papers

    Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

    by Francesca Conradie, Tatevik R. Bagdasaryan, Sergey Borisov, Pauline Howell, Lali Mikiashvili, Nosipho Ngubane, Anastasia Samoilova, Sergey Skornykova, Elena Tudor, Ebrahim Variava, et al.

    The bedaquiline–pretomanid–linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose of linezolid and duration of treatment with this agent to minimize toxic effects while maintaining efficacy against highly drug-resistant tuberculosis are unclear. We enrolled participants with extensively drug-resistant (XDR) tuberculosis (i.e., resistant to rifampin, a fluoroquinolone, and an aminoglycoside), pre-XDR tuberculosis (i.e., resistant to rifampin and to either a fluoroquinolone or an aminoglycoside), or rifampin-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. We randomly assigned the participants to receive bedaquiline for 26 weeks (200 mg daily for 8 weeks, then 100 mg daily for 18 weeks), pretomanid (200 mg daily for 26 weeks), and daily linezolid at a dose of 1200 mg for 26 weeks or 9 weeks or 600 mg for 26 weeks or 9 weeks. The primary end point in the modified intention-to-treat population was the incidence of an unfavorable outcome, defined as treatment failure or disease relapse (clinical or bacteriologic) at 26 weeks after completion of treatment. Safety was also evaluated. A total of 181 participants were enrolled, 88% of whom had XDR or pre-XDR tuberculosis. Among participants who received bedaquiline–pretomanid–linezolid with linezolid at a dose of 1200 mg for 26 weeks or 9 weeks or 600 mg for 26 weeks or 9 weeks, 93%, 89%, 91%, and 84%, respectively, had a favorable outcome; peripheral neuropathy occurred in 38%, 24%, 24%, and 13%, respectively; myelosuppression occurred in 22%, 15%, 2%, and 7%, respectively; and the linezolid dose was modified (i.e., interrupted, reduced, or discontinued) in 51%, 30%, 13%, and 13%, respectively. Optic neuropathy developed in 4 participants (9%) who had received linezolid at a dose of 1200 mg for 26 weeks; all the cases resolved. Six of the seven unfavorable microbiologic outcomes through 78 weeks of follow-up occurred in participants assigned to the 9-week linezolid groups. A total of 84 to 93% of the participants across all four bedaquiline–pretomanid–linezolid treatment groups had a favorable outcome. The overall risk–benefit ratio favored the group that received the three-drug regimen with linezolid at a dose of 600 mg for 26 weeks, with a lower incidence of adverse events reported and fewer linezolid dose modifications. (Funded by the TB Alliance and others; ZeNix ClinicalTrials.gov number, NCT03086486.)


  • Open Access

    Improving clinical trial interpretation with ACCEPT analyses

    by Michelle N. Clements, Ian R. White, Andrew J. Copas, Victoria Cornelius, Suzie Cro, David T Dunn, Matteo Quartagno, Rebecca M. Turner, Conor D. Tweed, A. Sarah Walker

    Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion both in trial design and in comparing results across trials. ACceptability Curve Estimation using Probability Above Threshold (ACCEPT) aids comparison between trials (even where of different designs) by harmonising reporting of results, acknowledging different interpretations of the results may be valid in different situations, and moving the focus from comparison to a pre-specified value to interpretation of the trial data. ACCEPT can be applied to historical trials or incorporated into statistical analysis plans for future analyses. An online tool enables ACCEPT on up to three trials simultaneously.

  • Open Access

    Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial

    by Annabelle South, Nalinie Joharatnam-Hogan, Cara Purvis, Elizabeth C. James, Carlos Diaz-Montana, William J. Cragg, Conor Tweed, Archie Macnair, Matthew R. Sydes, Claire Snowdon, et al.

    Background: Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no Email List Invitation to see which approach resulted in the highest patient satisfaction with how the results were communicated.Methods and findings: We carried out a cluster randomised, 2 by 2 by 2 factorial, nonblinded study within a trial, with semistructured qualitative interviews with some patients (ISRCTN96189403). Each cluster was a UK hospital participating in the ICON8 ovarian cancer trial. Interventions were shared with 384 ICON8 participants who were alive and considered well enough to be contacted, at 43 hospitals. Hospitals were allocated to share results with participants through one of the 8 intervention combinations based on random permutation within blocks of 8, stratified by number of participants. All interventions contained a written plain English summary of the results. The Enhanced Webpage also contained a short video. Both the Enhanced Webpage and Email contained links to further information and support. The Mailed Printed Summary was opt-out.Follow-up questionnaires were sent 1 month after patients had been offered the interventions. Patients’ reported satisfaction was measured using a 5-point scale, analysed by ordinal logistic regression estimating main effects for all 3 interventions, with random effects for site, restricted to those who reported receiving the results and assuming no interaction. Data collection took place in 2018 to 2019.Questionnaires were sent to 275/384 randomly selected participants and returned by 180: 90/142 allocated Basic Webpage, 90/133 Enhanced Webpage; 91/141 no Mailed Printed Summary, 89/134 Mailed Printed Summary; 82/129 no Email List Invitation, 98/146 Email List Invitation. Only 3 patients opted out of receiving the Mailed Printed Summary; no patients signed up to the email list. Patients’ satisfaction was greater at sites allocated the Mailed Printed Summary, where 65/81 (80%) were quite or very satisfied compared to sites with no Mailed Printed Summary 39/64 (61%), ordinal odds ratio (OR) = 3.15 (1.66 to 5.98,p< 0.001). We found no effect on patient satisfaction from the Enhanced Webpage, OR = 1.47 (0.78 to 2.76,p= 0.235) or Email List Invitation, OR = 1.38 (0.72 to 2.63,p= 0.327). Interviewees described the results as interesting, important, and disappointing (the ICON8 trial found no benefit). Finding out the results made some feel their trial participation had been more worthwhile. Regardless of allocated group, patients who received results generally reported that the information was easy to understand and find, were glad and did not regret finding out the results. The main limitation of our study is the 65% response rate.Conclusions: Nearly all respondents wanted to know the results and were glad to receive them. Adding an opt-out Mailed Printed Summary alongside a webpage yielded the highest reported satisfaction. This study provides evidence on how to share results with other similar trial populations. Further research is needed to look at different results scenarios and patient populations.Trial registration: ISRCTN:ISRCTN96189403.


  • Open Access

    A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

    by C. D. Tweed, G. H. Wills, A. M. Crook, E. Amukoye, V. Balanag, A. Y.L. Ban, A. L.C. Bateson, M. C. Betteridge, W. Brumskine, J. Caoili, et al.

    BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ) or 4 months (4Pa200MZ); 100 mg pretomanid daily for 4 months in the same combination (4Pa100MZ); or standard DS-TB treatment for 6 months. The primary outcome was treatment failure or relapse at 12 months post-randomisation. The non-inferiority margin for between-group differences was 12.0%. Recruitment was paused following three deaths and not resumed.RESULTS: Respectively 4/47 (8.5%), 11/57 (19.3%), 14/52 (26.9%) and 1/53 (1.9%) DS-TB outcomes were unfavourable in patients on 6Pa200MZ, 4Pa200MZ, 4Pa100MZ and controls. There was a 6.6% (95% CI –2.2% to 15.4%) difference per protocol and 9.9% (95%CI –4.1% to 23.9%) modified intention-to-treat difference in unfavourable responses between the control and 6Pa200MZ arms. Grade 3+ adverse events affected 68/203 (33.5%) receiving experimental regimens, and 19/68 (27.9%) on control. Ten of 203 (4.9%) participants on experimental arms and 2/68 (2.9%) controls died.CONCLUSION: PaMZ regimens did not achieve non-inferiority in this under-powered trial. An ongoing evaluation of PMD remains a priority.


  • Open Access

    Improving the Induction of PPI Contributors on Trial Oversight Committees

    by Emily C Pickering, Bec Hanley, Philip Bell, Jacqui Gath, Patrick Hanlon, Robert Oldroyd, Richard Stephens, Conor D Tweed

    Clinical Trials Units are encouraged to integrate Patient and Public Involvement (PPI) into all aspects of trial design, delivery, oversight and dissemination. This research explored the induction and training of PPI Contributors joining trial oversight committees. It was used to create an induction pack for new PPI Contributors at the Medical Research Council Clinical Trials Unit at University College London’s (MRC CTU at UCL). We have made this resource available to all researchers and in this we report describe the methodology behind its production.